BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline
BPC-157: The Gastric Peptide With 100+ Preclinical Studies and Near-Zero Human Trial Data — What the July PCAC Review and MHRA Scrutiny Mean for Research Procurement
BPC-157 is arguably the most discussed peptide in the current FDA regulatory cycle, yet its human evidence base remains strikingly thin. With a PCAC advisory vote scheduled for 23–24 July 2026 and the MHRA having opened a separate investigation into UK clinics making claims about the compound, research-procurement professionals need a clear-eyed picture of where the science, the regulation, and the supply chain actually stand.
30 Jun 2026
Research Pipeline
Epitalon: The Pineal Tetrapeptide at the Centre of the July 2026 PCAC Review — What the Evidence and Regulatory Shift Mean for Research Procurement
Epitalon (Ala-Glu-Asp-Gly), a synthetic tetrapeptide derived from pineal gland research, is among the seven compounds scheduled for formal FDA Pharmacy Compounding Advisory Committee review on 24 July 2026. With removal from Category 2 confirmed in April and written comments to the docket due by 9 July, UK research procurement teams need a clear-eyed account of its evidence base, remaining regulatory unknowns, and the supply-chain pressures now bearing on peptide API sourcing.
28 Jun 2026
Research Pipeline
MOTS-c: The Mitochondrial-Derived Peptide Facing Its First Major Regulatory Reckoning at the July 2026 PCAC
MOTS-c — a 16-amino-acid peptide encoded by the mitochondrial genome — is scheduled for FDA Pharmacy Compounding Advisory Committee review on 23 July 2026, making it one of the more scientifically distinctive compounds on the Day-One agenda. This briefing covers its mechanism, the state of clinical evidence, its WADA prohibition, current regulatory grey-zone status, and what the PCAC outcome means for UK research procurement teams.
27 Jun 2026
Research Pipeline
Selank: The Tuftsin-Derived Anxiolytic Peptide Absent from the July PCAC — What the Regulatory Grey Zone Means for Research Procurement
Selank is a synthetic heptapeptide with Russian clinical approval for generalised anxiety disorder and one of the better-documented evidence bases among research peptides. Yet it carries no July 2026 PCAC slot, no FDA-authorised compounding pathway, and sits in a regulatory grey zone that procurement teams must understand before sourcing.
26 Jun 2026
Research Pipeline
Retatrutide: What the TRIUMPH-1 Phase 3 Data and NDA Timeline Mean for Peptide Research Procurement
Eli Lilly's triple-agonist retatrutide posted a 28.3% average weight loss at 80 weeks in the Phase 3 TRIUMPH-1 trial — the largest efficacy signal ever recorded in a randomised obesity study. With an NDA submission targeted for Q4 2026 and a grey market already active, procurement teams need to understand what the compound is, where it stands legally, and how to source it responsibly for legitimate research.
25 Jun 2026
Research Pipeline
TB-500: What a June 2026 Scoping Review and the July PCAC Agenda Mean for Research Procurement
A peer-reviewed scoping review published on 19 June 2026 maps the TB-500 and thymosin beta-4 evidence base and finds the human clinical literature remains sparse. Combined with the peptide's inclusion on the FDA PCAC Day 1 agenda for 23 July 2026 and its continued prohibition under the 2026 WADA Prohibited List, procurement teams face a layered due-diligence picture that is more complex than the compound's popularity suggests.
24 Jun 2026
Research Pipeline
Thymosin Alpha-1: The Internationally Approved Immune Peptide in Regulatory Limbo — What the PCAC Vote and Category 2 Removal Mean for Research Procurement
Thymosin alpha-1 is the most clinically validated immune-modulating peptide in the research catalogue — approved as Zadaxin in over 35 countries and evaluated in more than 80 clinical trials. Yet in the United States it remains without FDA approval, was removed from Category 2 in September 2024, and was voted down 4-17 by the PCAC in December 2024. It is not scheduled for the July 2026 PCAC meeting. This briefing examines what that regulatory history means for UK research procurement in…
22 Jun 2026
Research Pipeline
CJC-1295 and Ipamorelin: The Growth Hormone Pair Left Out of the July 2026 PCAC — What the Regulatory Limbo Means for Research Procurement
CJC-1295 and Ipamorelin are among the most widely studied growth hormone secretagogue peptides, yet they occupy a regulatory position distinct from the twelve substances currently heading for the July 2026 PCAC review. A 2024 advisory committee already voted against their inclusion on the 503A Bulks List, and neither compound appears on either scheduled PCAC agenda. Research procurement teams need to understand what that means for legitimate sourcing and laboratory use.
21 Jun 2026
Research Pipeline
GHK-Cu: The Copper Tripeptide Caught Between Two Regulatory Categories — and What It Means for Research Procurement
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) holds a singular position in the 2026 peptide regulatory landscape: it is the only compound among the twelve removed from FDA Category 2 that has simultaneously been withdrawn from Category 1, leaving it in a distinct limbo ahead of a scheduled PCAC review before February 2027. This briefing outlines the compound's biochemistry, the current state of clinical evidence, and the procurement implications for UK research laboratories.
20 Jun 2026
Research Pipeline
BPC-157: What the 2026 Evidence Review, New Human Trial and Dual Regulatory Scrutiny Mean for Research Procurement
A March 2026 peer-reviewed review reinforces BPC-157's preclinical tissue-repair profile, yet human clinical data remain sparse and a newly registered controlled trial is the first to formally test the peptide in a musculoskeletal injury population. Meanwhile, the MHRA has opened investigations into UK clinics making unlicensed therapeutic claims, and the FDA is set to scrutinise the compound at its July 2026 PCAC meeting. Research-procurement teams need a clear picture of what is known, what…
19 Jun 2026
Research Pipeline
TB-500: What the First Human RCT and 2026 Regulatory Reclassification Mean for Research Procurement
A Phase 1/2 randomised controlled trial of TB-500 in adults with stable cardiovascular disease — the first interventional human study of the 17-amino acid fragment specifically — began enrolment in early 2026. Simultaneously, the February 2026 FDA reclassification placed TB-500 in the 503A Category 2 prohibited list, reshaping how UK and US research labs can legitimately source the compound.
13 Jun 2026
Research Pipeline
GLP-1 Receptors and Oncology: What the ASCO 2026 Evidence Cluster Means for Research Procurement
A cluster of five real-world studies presented at the 2026 American Society of Clinical Oncology Annual Meeting has elevated GLP-1 receptor agonists as a serious subject of oncology research, with signals across metastatic progression, breast cancer prevention, and immune checkpoint inhibitor outcomes. For research-procurement teams, the findings point to growing demand for characterised GLP-1 peptide material beyond metabolic applications.
10 Jun 2026